![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Through the acquisition, Rosemont will expand its existing portfolio and have access to a pipeline of innovative products including, alimemazine tartrate, an oral solution, used for the management of urticaria and pruritus.
Lead Product(s): Alimemazine
Therapeutic Area: Dermatology Product Name: Alimemazine Tartrate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rosemont
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 16, 2023